



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/807,489	07/31/2001	Isabel Antonia Maria Van Waterschoot	01-468	9467

20306 7590 04/18/2005

MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606

EXAMINER

GHALI, ISIS A D

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED: 04/18/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/807,489

Applicant(s)

VAN WATERSCHOOT ET AL.

Examiner

Isis Ghali

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 December 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4, 6, 7, 15, 18-21 and 25 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4, 6, 7, 15, 18-21 and 25 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The receipt is acknowledged of applicants' amendment and request for extension of time, both filed 12/27/2004.

Claims 5, 8-14, 16, 17, 22-24 have been canceled, and claim 25 has been added.

Claims 1-4, 6, 7, 15, 18-21, and 25 are pending and included in the prosecution.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claim 18 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for promoting lactation in female mammal by administering ARA in an edible formulation, does not reasonably provide enablement for promoting reproductive efficiency or success, or fertility. Further, the specification has enabled administering ARA in an edible formulation, but has not enabled any other route of administering ARA. The specification does not enable any person skilled in the

art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: the nature of the invention; the breadth of the claims; the state of the prior art; the relative skill of those in the art; the amount of direction or guidance presented; the predictability or unpredictability of the art; the presence or absence of working examples; and the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

The nature of the invention: The nature of the invention is an edible formulation such as a dietary supplement comprising ARA by itself or in combination with and DHA and method of its use for pregnant or lactating mammals to promote lactation. The nature of the invention is complex in that it encompasses varieties of formulations comprising ARA and DHA used for multiple complex disorders having unrelated manifestations and etiology, and subsequently treated by administering the instant edible formulation. The entire specification disclosed edible formulation in form of dietary supplement, pill, tablet, capsule or gelatin capsule comprising ARA or combination of ARA and DHA used as dietary supplement to promote lactation in lactating mammals, examples 1-6. Nowhere in the specification applicants disclosed formulations other than edible formulation, or uses other than dietary supplement for

pregnant and lactating mammals. Further, the specification does not enable the promotion of reproductive efficiency or success or fertility as claimed.

The breadth of the claims: The claim is broad. The claim encompasses all varieties of pharmaceutical compositions including oral, topical, parenteral or edible compositions. The claim encompasses promotion of complex disorders that may have potential causes other than those disclosed in the specification that are related to ARA and/or DHA deficiency. This may or may not be addressed by the administration of the instant edible formulation comprising ARA. For example infertility can be caused by hormonal disturbance that needs hormonal therapy; or can be caused by fallopian tube sclerosis or adhesion that needs surgical interference. Moreover, the specification is directed to dietary supplement for pregnant or lactating mammals, however, other disorders, such as infertility disorders are encompassed by the instant claims. Further, the claims encompass all the forms of the pharmaceutical composition, while only dietary supplement is disclosed.

The state of the prior art: The state of the art does not recognize the administration of composition comprising ARA to promote reproductive efficiency or success or fertility. The state of the art recognizes the administration of dietary supplement comprising ARA and DHA to the pregnant and lactating human and animals, US 6,200,624.

The relative skill of those in the art: The relative skill of those in the art is high.

The amount of direction or guidance presented: The guidance given by the specification on how to promote reproductive efficiency or success or fertility is absent.

No evidence is provided regarding promotion of fertility. Guidance for a capsule used as dietary supplement to promote lactation is provided. Furthermore, the specification provides no guidance, in the way written description, on any pharmaceutical compositions other than dietary supplement. The specification provides guidance on edible formulation comprising DHA and/or ARA such as dietary supplement, tablet, pill or capsule, page 3, lines 13-14 of the present specification. It is not obvious from the disclosure of capsule comprising DHA and/or ARA used as a dietary supplement for pregnant and lactation mammals if other formulations for other uses will work, e.g. topical formulation comprising ARA would promote fertility in an infertile mammal. *In re Dreshfield*, 110 F.2d 235, 45 USPQ 36 (CCPA 1940), gives this general rule: "It is well settled that in cases involving chemicals and chemical compounds, which differ in their properties it must appear in an applicant's specification either by the enumeration of a sufficient number of the members of a group or by other appropriate language, that the chemicals or chemical combinations included in the claims are capable of accomplishing the desired result." The article "Broader than the Disclosure in Chemical Cases," 31 J.P.O.S. 5, by Samuel S. Levin covers this subject in detail. A disclosure should contain representative examples which provide reasonable assurance to one skilled in the art that the compounds fall within the scope of a claim will possess the alleged activity. See *In re Riat et al.* (CCPA 1964) 327 F2d 685, 140 USPQ 471; *In re Barr et al.* (CCPA 1971) 444 F 2d 349, 151 USPQ 724.

The predictability or unpredictability of the art: The lack of significant guidance from the specification or prior art with regard to formulations other than edible

formulation comprising ARA that promote fertility makes practicing the claimed invention unpredictable in terms of using other formulations for promoting fertility that may have causes other than fatty acid deficiency and require completely different approach.

The presence or absence of working examples: The specification discloses only edible formulation such as dietary supplement or capsule comprising ARA and/or DHA used for pregnant and lactating mammals, examples 1-6. No working examples to show formulations other than edible formulation used to promote fertility as recited in the claim. Therefore, the specification has only enabled edible formulation in the form of capsule or dietary supplement comprising ARA and DHA for pregnant and lactating mammals.

The quantity of experimentation necessary: Therefor, the practitioner would turn to trial and error experimentation to practice the instant method for promoting fertility that may have potential causes other than ARA and DHA deficiency without guidance from the specification or the prior art. Also, the practitioner would turn to trial and error experimentation to practice the instant method in term of other formulations other than the edible formulation for promoting lactation without guidance from the specification or the prior art. Therefore, undue experimentation becomes the burden of the practitioner.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1615

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

4. Claim 15 is rejected under 35 U.S.C. 102(e) as being anticipated by US 6,200,624 ('624).

US '624 discloses a nutritional supplement comprising ARA and DHA that can be administered to pregnant or lactating human and animal females (title, abstract; col.17, lines 31-38). The supplement comprises 0.1- 5% DHA and 1-15% ARA (col.30, lines 15-22).

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

7. Claims 1-4, 6, 7, 15, 18-21, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 6,200,624 ('624).

US '624 teaches a nutritional supplement comprising ARA and DHA that can be administered to pregnant or lactating human and animal females (title, abstract; col.17, lines 31-38). The supplement comprises 0.1- 5% DHA and 1-15% ARA (col.30, lines 15-22).

US '624 does not teach the amount of each of ARA and DHA and their ratios, or the profile of administration of ARA. The reference does not teach clearly the promotion of lactation, but this limitation is implied by the teaching of administering the dietary supplement for lactating human or animal.

It is within the skill in the art to determine the profile of administration of a pharmaceutical formulation and the amount and ratios of different ingredients in order to achieve the desired effect. Thus, the claimed amounts and ratios, and profile of use are not considered critical since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233. It is also within the skill in the art to use formulation comprising ARA and DHA to treat conditions or disorders known to be caused by the deficiency of these fatty acids.

8. Claims 1, 2, 6, 7, 15 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 98/16119 ('119).

WO '119 teaches an edible formulation comprising ARA used as foods for pregnant and lactating mothers (abstract).

WO '119 does not teach the amounts and the profile of administration of ARA, or the promotion of lactation in non-human mammal.

The administration to non-human mammal is implied by the teaching of the reference, and does not impart patentability to the claims, absent evidence to the contrary.

The amounts and profiles are not considered critical since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233.

9. Claims 3, 4, 19-21 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO '119 in view of Makrides et al.

WO '119 teaches an edible formulation comprising ARA used as foods for pregnant and lactating mothers (abstract).

WO '119 does not teach combining DHA with ARA, or the amount of DHA and the ratios of ARA: DHA.

The amount and ratios do not impart patentability to the claims, absent evidence to the contrary.

Makrides et al. teach method to increase the DHA in breast milk by dietary supplementation of DHA in amount 0.2-1.3 g/day.

Thus, it would have been obvious to one having ordinary skill in the art at the time of the invention to add DHA to the dietary composition comprising ARA for the pregnant or lactating women disclosed by WO '119, motivated by the teaching of Makrides et al. that DHA in the dietary supplement increases the DHA in the breast milk, with reasonable expectation of having a dietary supplement comprising ARA and DHA to be administered to the pregnant and lactating mother to successfully promote lactation.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Isis Ghali whose telephone number is (571) 272-0595. The examiner can normally be reached on Monday-Thursday, 7:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Isis Ghali
Examiner
Art Unit 1615

IG

Isis Ghali

ISIS GHALI
PATENT EXAMINER